达格列净联合维立诺雷德与非布司他进一步降低高尿酸血症患者血尿酸:QUARTZ研究
QUARTZ研究为随机、安慰剂对照、两阶段交叉试验,纳入36例无症状高尿酸血症成人,比较维立诺雷德9mg+非布司他80mg+达格列净10mg与同方案加安慰剂各7天。两方案均降低尿尿酸排泄峰值,达格列净组血尿酸较安慰剂组进一步降低(平均治疗差-62.3 µmol/L),且未影响尿尿酸排泄或安全性参数。
要点
- 达格列净联合维立诺雷德和非布司他可进一步降低血尿酸,平均治疗差-62.3 µmol/L。
- 联合方案未增加尿尿酸排泄峰值,两方案均较基线下降。
- 达格列净未影响维立诺雷德、非布司他药代动力学及空腹血糖。
核心结论
- 达格列净联合维立诺雷德和非布司他可进一步降低血尿酸,且不增加尿尿酸排泄,提示该联合方案在所测剂量下不 adverse 影响肾功能。
研究设计与样本
- 随机、安慰剂对照、两阶段交叉研究(NCT03316131),纳入36例无症状高尿酸血症成人。
主要发现
- 两方案均降低尿尿酸排泄峰值:达格列净组最小二乘均值变化-12.9 mg/h(95%CI -21.0至-4.7),安慰剂组-13.2 mg/h(95%CI -21.3至-5.0)。
- 达格列净组血尿酸浓度较安慰剂组更低,平均治疗差-62.3 µmol/L(95%CI -82.8至-41.8)。
- 达格列净未影响维立诺雷德及其主要代谢物、非布司他或空腹血糖水平,安全性参数无临床相关变化。
临床怎么用
- 对于高尿酸血症患者,可考虑在维立诺雷德联合非布司他基础上加用达格列净以进一步降低血尿酸,但需注意该研究为短期交叉设计。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Combining a sodium-glucose cotransporter 2 inhibitor with a xanthine oxidase inhibitor (XOI) and a urate transporter 1 (URAT1) inhibitor may enhance serum uric acid (sUA) lowering. However, concerns exist regarding high urinary UA (uUA) excretion rates and subsequent crystallization in renal tubules. OBJECTIVE: To assess whether dapagliflozin added to verinurad, a selective URAT1 inhibitor, and febuxostat, an XOI, increases uUA excretion. DESIGN: Randomized, placebo-controlled, 2-way crossover study (NCT03316131). PATIENTS: Adults with asymptomatic hyperuricemia. INTERVENTIONS: Subjects (N = 36) were randomized to oral once-daily 9 mg verinurad plus 80 mg febuxostat plus 10 mg dapagliflozin for 7 days and 7 days of oral once-daily 9 mg verinurad plus 80 mg febuxostat plus placebo with an intervening 7- to 21-day washout period. MAIN OUTCOME MEASURE: Difference in peak uUA excretion between groups from baseline to day 7. Secondary outcomes included changes in sUA levels and 24-h uUA excretion. RESULTS: Both regimens lowered mean peak uUA excretion (least squares mean changes from baseline: -12.9 mg/h [95% confidence interval (CI): -21.0 to -4.7], dapagliflozin; -13.2 mg/h [95% CI -21.3 to -5.0], placebo). sUA concentrations were lower with dapagliflozin (mean treatment difference -62.3 µmol/L [95% CI -82.8 to -41.8]). Dapagliflozin did not impact verinurad pharmacokinetics, its main metabolites, or febuxostat or fasting plasma glucose levels vs verinurad plus febuxostat. There were no clinically relevant changes in safety parameters. CONCLUSIONS: Dapagliflozin further reduced sUA without influencing uUA excretion, suggesting that its combination with verinurad and febuxostat at the doses tested does not adversely affect kidney function. CLINICAL TRIAL REGISTRATION NUMBER: NCT03316131.
引用
- Stack AG, Han D, Goldwater R, et al. Dapagliflozin Added to Verinurad Plus Febuxostat Further Reduces Serum Uric Acid in Hyperuricemia: The QUARTZ Study. J Clin Endocrinol Metab. 2021. PMID: 33075806. doi:10.1210/clinem/dgaa748
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。